相关实验视频

Updated: May 20, 2025

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

E2F2 ((E2F转录因子2) 作为梅博米腺癌的潜在治疗点:功能和表观遗传学研究的证据

Wei Wang¹, Hetong Wang¹, Xun Liu¹

¹Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, 300384, China.

|May 16, 2025

概括

这项研究揭示了E2F2 (E2F转录因子2) 在梅博米腺癌 (MGC) 中被下调,并起到瘤抑制作用. 抑制DNA甲基化可以恢复E2F2的表达,为MGC提供了潜在的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

梅博米腺癌 (MGC) 是一种具有不良预后的侵袭性眼瘤.
异常的E2F转录因子2 (E2F2) 表达涉及到MGC的发病,可能是由于DNA甲基化.
调查E2F2的作用对于理解MGC发展至关重要.

研究的目的:

研究MGC的分子机制,重点关注E2F2.2的作用.
探索E2F2表达,DNA甲基化和MGC进展之间的关系.
确定E2F2作为MGC的潜在治疗点.

主要方法:

在MGC组织和细胞中分析E2F2表达.
功能性测试 (CCK8,伤口愈合,Transwell) 来评估MGC细胞在E2F2调制后的行为.
流细胞计用于细胞亡和细胞循环分析.
RNA测序和甲基化特异性PCR (MSP) 以评估甲基化抑制剂5-aza-2'-deoxycytidine (5-aza-2-dc) 对基因表达和甲基化水平的影响.

主要成果:

与正常组织相比,MGC中的E2F2表达显着较低,与Ki-67负相关,与P21/P27.7正相关.
抑制E2F2促进了MGC细胞的增殖,迁移和入侵,同时减少了细胞亡和改变细胞周期阶段.
使用5-aza-2-dc上调调节E2F2表达,逆转基因沉默和抑制MGC细胞恶性瘤来抑制DNA甲基化.
在甲基化抑制后差异表达的基因主要参与DNA复制和细胞循环途径.

结论:

在MGC中,E2F2作为瘤抑制剂起作用.
通过甲基化抑制恢复E2F2表达,为MGC提供了一个有前途的治疗策略.
针对E2F2和甲基化通路提供了精确,个性化的MGC治疗的潜力.

关键词:

5-aza-2'-deoxycytidine的使用情况细胞循环细胞循环 E2F2 E2F2 E2F2 E2F2 E2F2 E2F2 梅博姆腺癌是梅博姆腺癌.RNA 测序 DNA 甲基化

更多相关视频

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction

Published on: April 1, 2019

Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development

Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development

Published on: September 4, 2021

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Master Transcription Regulators

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...